Degradation of molecules in thawed biological samples is one of the biggest challenges for all bioanalytical laboratories. During the January SLAS conference in San Diego, CA, CryoXtract was nominated for an innovation award based on a study of the use of frozen aliquotting for the bioanalysis of labile compounds (found here). During a podium presentation, authors Glenn Smith and Joe Fraone outlined the results of the collaborative study with GlaxoSmithKline.
An article appearing in R and D Magazine (found here) echoes CryoXtract’s call for careful and consistent procedures for sample handling and maintenance at biobanks. Without thoughtful attention to process and temperature controls, sample integrity can be compromised which can negatively impact critical research in the life sciences field.
The following are indexed audio files of the full interview between Larry Chin, Vice President of Business Development at CryoXtract, and Dee McGarvey, Director, CHTN Eastern Division, University of Pennsylvania.
The biobanking industry needs to address growing information technology demands in order to be able to execute on best practices for research now and in the future, said Dee McGarvey, Director, CHTN Eastern Division, University of Pennsylvania, in an interview.
Biobank databases, for example, need to be comprehensive enough to hold large amounts of information and at the same time provide flexibility so that they can connect with a variety of complementary information systems. As the systems are designed and implemented, of primary concern is ensuring security since Patient Health Information (PHI) is involved.
“That’s probably one of the biggest issues that biobanks are working with right now,” McGarvey said. "How do you manage to keep the databases open so we can use them and access them and they can interact with all the other systems? How can we work within this framework and at the same time, maintain the security?”